Limit Confusion and Other Issues With Paxlovid

Please see the FDA announcement authorizing pharmacists to prescribe Paxlovid with certain limitations.

You can help prevent problems when patients taking nirmatrelvir/ritonavir (Paxlovid) for COVID-19 are admitted.

High-risk OUTpatients with a positive COVID-19 test should start this antiviral combo within 5 days of symptom onset.

And if a patient is hospitalized before the course is complete, clinicians may want to finish it.

Document details about nirmatrelvir/ritonavir on med histories...especially med strength and when the course was started.

Most patients will get a 300 mg/100 mg dose pack...and take 2 nirmatrelvir tabs plus 1 ritonavir tab bid for 5 days.

But some patients with kidney disease may need the 150 mg/100 mg pack...with just 1 nirmatrelvir tab and 1 ritonavir tab bid for 5 days.

Be aware that drug interactions can be an issue when patients take nirmatrelvir/ritonavir...such as with most statins (simvastatin, etc) and some blood thinners (apixaban, etc).

Ask if any home meds were stopped...or doses adjusted...when nirmatrelvir/ritonavir was started. Note this on the med history so that clinicians can restart or readjust doses when appropriate.

Anticipate usually using a patient’s own med if nirmatrelvir/ritonavir is continued while they’re in-house.

Alert your pharmacist if a patient’s supply is depleted, but there’s still an active order in your EHR. The prescriber may not have included the right stop date.

Key References

  • (6-29-22)
  • (6-29-22)
  • (6-29-22)
  • (6-29-22)
Hospital Pharmacy Technician's Letter. July 2022, No. 380710


Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote